1. Home
  2. News
  3. News

News

Receives TFDA approval to conduct phase II clinical trial of AD17002 for the treatment of moderate-to-severe eosinophilic asthma.

Receives TFDA approval to conduct phase II clinical trial of AD17002 for the treatment of moderate-to-severe eosinophilic asthma.

2025-08-11
公開資訊觀測站精華版 本資料由　(興櫃公司) 6709 昱厚生技 　公司提供 序號 1 發言日期 114/08/11 發言時間 16:03:38 發言人 徐悠深 發言人職稱 ...
More
Submits IND application to TFDA for phase II clinical trial of AD17002 in the treatment of moderate-to-severe eosinophilic asthma.

Submits IND application to TFDA for phase II clinical trial of AD17002 in the treatment of moderate-to-severe eosinophilic asthma.

2025-06-16
公開資訊觀測站精華版 本資料由　(興櫃公司) 6709 昱厚生技 　公司提供 序號 2 發言日期 114/06/16 發言時間 15:30:42 發言人 徐悠深 發言人職稱 ...
More
Submits interim analysis report of AD17002 nasal spray for asthma treatment to TFDA and announces early termination of the clinical trial.

Submits interim analysis report of AD17002 nasal spray for asthma treatment to TFDA and announces early termination of the clinical trial.

2025-03-05
公開資訊觀測站精華版 本資料由　(興櫃公司) 6709 昱厚生技 　公司提供 序號 2 發言日期 114/03/05 發言時間 18:01:55 發言人 徐悠深 發言人職稱 ...
More
The results of the Phase 2a clinical trial of the nasal spray COVID-19 immunotherapy drug AD17002 were published in the journal Human Vaccines & Immunotherapeutics. The study demonstrates that AD17002 shows good safety and tolerability in patients wit

The results of the Phase 2a clinical trial of the nasal spray COVID-19 immunotherapy drug AD17002 were published in the journal Human Vaccines & Immunotherapeutics. The study demonstrates that AD17002 shows good safety and tolerability in patients wit

2024-12-11
More
Advagene has been invited to participate in the Host Directed Therapeutics Industry Day and the JPEO CBRND, and has been selected to deliver a verbal presentation to U.S. Government representatives.

Advagene has been invited to participate in the Host Directed Therapeutics Industry Day and the JPEO CBRND, and has been selected to deliver a verbal presentation to U.S. Government representatives.

2024-10-23
More
公告本公司董事會決議現金增資發行新股案

公告本公司董事會決議現金增資發行新股案

2024-05-23
公開資訊觀測站精華版 本資料由　(興櫃公司) 6709 昱厚生技 　公司提供 序號 1 發言日期 113/05/23 發言時間 15:20:36 發言人 徐悠深 發言人職稱 總經理 發言人電話 ...
More
本公司受邀參加福邦證券及環球生技月刊舉辦之「生醫產業趨勢暨企業投資論壇」

本公司受邀參加福邦證券及環球生技月刊舉辦之「生醫產業趨勢暨企業投資論壇」

2024-04-17
公開資訊觀測站精華版 本資料由　(興櫃公司) 6709 昱厚生技 　公司提供 序號 1 發言日期 113/04/17 發言時間 16:08:21 發言人 徐悠深 發言人職稱 總經理 發言人電話 ...
More
本公司鼻噴新藥AD17002治療氣喘臨床二期試驗案收受首位受試者

本公司鼻噴新藥AD17002治療氣喘臨床二期試驗案收受首位受試者

2023-11-30
公開資訊觀測站精華版 本資料由　(興櫃公司) 6709 昱厚生技 　公司提供 序號 2 發言日期 112/11/30 發言時間 16:56:02 發言人 徐悠深 發言人職稱 ...
More
Results of the phase IIa human clinical trial of the new drug AD17002-SC for the treatment of COVID-19 showed good safety, tolerability, and the efficacy in virus clearance.

Results of the phase IIa human clinical trial of the new drug AD17002-SC for the treatment of COVID-19 showed good safety, tolerability, and the efficacy in virus clearance.

2023-10-03
公開資訊觀測站精華版 序號 1 發言日期 112/10/03 發言時間 17:39:52 發言人 徐悠深 發言人職稱 董事長 發言人電話 27970073 主旨 公告本公司新藥AD17002-SC治療新冠肺炎二a期人體臨...
More
Obtained IND approval by TFDA to conduct phase II clinical trials of the new drug AD17002 for the treatment of patients with eosinophilic asthma.

Obtained IND approval by TFDA to conduct phase II clinical trials of the new drug AD17002 for the treatment of patients with eosinophilic asthma.

2023-04-16
公開資訊觀測站精華版 本資料由　(興櫃公司) 6709 昱厚生技 　公司提供 序號 1 發言日期 112/04/16 發言時間 13:11:38 發言人 徐悠深 發言人職稱 董事長 發言人電話 ...
More
The last subject of the Phase II clinical trial of the COVID-19 treatment in Taiwan completed the drug administration

The last subject of the Phase II clinical trial of the COVID-19 treatment in Taiwan completed the drug administration

2023-04-16
The last subject of the Phase II clinical trial of the COVID-19 treatment in Taiwan completed the drug administration.
More
The first subject participated in the phase II/III trial for the treatment of COVID-19 in Indonesia.

The first subject participated in the phase II/III trial for the treatment of COVID-19 in Indonesia.

2022-11-23
公開資訊觀測站精華版 本資料由　(興櫃公司) 6709 昱厚生技 　公司提供 序號 1 發言日期 111/11/23 發言時間 15:21:08 發言人 徐悠深 發言人職稱 董事長 發言人電話 ...
More
繁體中文
English
简体中文
This site uses cookies to collect the necessary user browsing behavior so that we can provide you with a better browsing experience. Browse this site, which means you agree with "online privacy declaration."